* denotes a publication that resulted from CTD2 intra-Network collaborations
Researchers show that basal- and luminal-derived prostate tumors have distinct molecular signatures.
Researchers introduce how CRISPR interference (CRISPRi) can efficiently repress expression of targeted genes in Escherichia coli, with no detectable off-target effects, and can be used to repress multiple target genes simultaneously.
Researchers describe a novel method to discern molecular interactions specific to certain molecular contexts.
The authors use ultracomplex pooled shRNA libraries (25 shRNAs/gene) to identify high-confidence hit genes for a given phenotype and effective shRNAs and construct double-shRNA libraries from these to systematically measure genetic interactions between hits.
Wnt/β-catenin signaling plays a key role in the pathogenesis of colon and other cancers; emerging evidence indicates that oncogenic β-catenin regulates several biological processes essential for cancer initiation and progression.
Researchers evaluate blocking the MET pathway to prevent post-bevacizumab treatment tumor recurrence, providing a strong rationale for using a combination of MET and VEGF receptor inhibitors to treat glioblastoma patients.
Researchers have developed an integrated systems-biology approach to identifying novel cancer genes contributing to endometrial tumorigenesis. Their results revealed 12 potential driver cancer genes including 10 tumor-suppressor candidates and two oncogene candidates.
Researchers created a mouse model of prostate cancer with inducuble PTEN disruption plus BRAF(V600E) expression.